SK Plasma announced on the 28th that it will begin full-fledged production this month after receiving product approval for blood products (albumin and immunoglobulin) from the Singapore Health Authority (HSA). The company will independently supply a total of 30 million dollars (39 billion won) worth of blood derivatives over the next six years, starting with the initial export in the fourth quarter. When the Singapore health authorities send plasma secured through their own blood source to SK Plasma, SK Plasma produces finished blood products such as albumin using the plasma as raw material at the Andong plant and sends it to Singapore.

In 2022, Singapore's health authorities designated SK Plasma's blo